Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-population trends in obesity across dimensions of inequality in England, 2019-25: a retrospective, longitudinal cohort study of 54 million adults.

The lancet. Diabetes & endocrinology·2026
Same author

Measurement of quality of stroke care with national electronic health records: a prospective cohort study during and after the COVID-19 pandemic.

BMJ open·2026
Same author

A Bayesian Location-Scale Joint Model for Time-To-Event and Multivariate Longitudinal Data With Association Based on Within-Individual Variability.

Statistics in medicine·2026
Same author

Adolescent Blood Pressure and Cardiovascular Disease Before Age 50 Years.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study.

Heart (British Cardiac Society)·2026
Same author

Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.

European heart journal·2026

Related Experiment Video

Updated: May 29, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

A framework for quantifying net benefits of alternative prognostic models.

Eleni Rapsomaniki1, Ian R White, Angela M Wood

  • 1Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. er339@medschl.cam.ac.uk

Statistics in Medicine
|September 10, 2011
PubMed
Summary

This study introduces a new framework to evaluate prognostic models by measuring their public health impact (net benefit) on treatment decisions. This approach quantifies health gains, offering a more clinically relevant assessment than traditional methods.

More Related Videos

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Related Experiment Videos

Last Updated: May 29, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

  • Biostatistics
  • Public Health
  • Health Economics

Background:

  • Traditional prognostic model evaluation lacks clinical and health economic context.
  • Existing measures of discrimination and risk reclassification are insufficient.
  • There is a need for methods that integrate prognostic performance with health economic impact.

Purpose of the Study:

  • To propose a novel framework for comparing prognostic models based on net benefit.
  • To quantify the public health impact of treatment decisions supported by prognostic models.
  • To link prognostic model performance directly to health economic outcomes.

Main Methods:

  • Developed a framework to quantify net benefit, representing public health impact.
  • Extended previous work by incorporating life years gained and accounting for time-to-event data.
  • Utilized an individual participant data meta-analysis for validation in a multi-study setting.
  • Adjusted for competing risks in cost-effectiveness comparisons.

Main Results:

  • The proposed net benefit framework provides more clinically interpretable results than traditional measures.
  • Demonstrated the estimation of cardiovascular-disease-free life years gained by using a more comprehensive risk prediction model.
  • Cost-effectiveness comparisons were shown to be robust across various modeling assumptions.

Conclusions:

  • The net benefit framework offers a superior method for evaluating prognostic models in clinical and health economic contexts.
  • This approach enhances the assessment of screening and risk reduction interventions.
  • The methodology is applicable to diverse prognostic modeling scenarios, including cardiovascular disease risk prediction.